EGFR-TKI治疗S768Ⅰ突变非小细胞肺癌的研究进展

段桦; 崔慧娟

doi:10.3969/j.issn.1000-8179.2017.22.824

EGFR-TKI治疗S768Ⅰ突变非小细胞肺癌的研究进展

doi: 10.3969/j.issn.1000-8179.2017.22.824

段桦^{①, ②,},
崔慧娟^①, ,

①.
中日友好医院中西医结合肿瘤内科（北京市100029）
②.
北京中医药大学

基金项目:

北京市科委首都特色应用研究项目 Z151100004015168

详细信息

作者简介:
段桦专业方向为中西医结合治疗肺癌。E-mail：duanhua1992@bucm.edu.cn

通讯作者:
崔慧娟 cuihj1963@sina.com

计量
- 文章访问数: 72
- HTML全文浏览量: 17
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2017-07-20
- 修回日期: 2017-09-08
- 刊出日期: 2017-11-30

Progress on EGFR-TKI in treatment of non-small cell lung cancer with S768Ⅰ mutation

DUAN Hua^{①, ②
,},
CUI Huijuan^{①
, ,}

①.
Department of Oncology of Integrative Medicine, China-Japan Friendship Hospital, Beijing 100029, China
②.
Beijing University of Chinese Medicine, Beijing 100029, China

Funds:

the Capital Application Research of Beijing Municipal Science and Technology Commission Z151100004015168

More Information

Corresponding author: Huijuan CUI; E-mail: cuihj1963@sina.com

摘要

摘要: 肺癌是死亡率较高的恶性肿瘤之一，近年来非小细胞肺癌（non-small cell lung cancer，NSCLC）的治疗进展迅速，尤其是表皮生长因子受体络氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitor，EGFR-TKI）的问世，使得携带EGFR基因敏感突变患者的中位无进展生存期（median progression free survival，mPFS）达到27.7个月，但部分不常见的EGFR突变对TKI的应答效果尚不十分明确。S768Ⅰ突变是EGFR20外显子携带的不常见突变之一，发生率为1%~2%。本文对不同代EGFR-TKI治疗S768Ⅰ单一或复合突变的研究进行综述，旨在为临床决策提供思路。
- EGFR-TKI /
- 20外显子 /
- S768Ⅰ突变 /
- 治疗进展
Abstract: Lung cancer is one of the malignant tumors with high mortality rates. In recent years, considerable progress on the treatment of non-small cell lung cancer has been achieved. Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) improves the median progression free survival of patients with sensitive mutations to 27.7 months. However, the therapeutic effect of EGFR-TKI on uncommon mutations remains unknown. S768Ⅰ mutation is an insensitive mutation in the EGFR20 exon, and its incidence rate ranges from 1% to 2%. In this review, the effect of different generation EGFR-TKI on single or complex S768Ⅰ mutation during treatment is discussed.
- epidermal growth factor receptor-tyrosine kinase inhibitor /
- exon /
- S768Ⅰ mutation /
- advances

HTML全文

参考文献(45)

[1]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. doi: 10.3322/caac.21262
[2]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA: A Cancer J Clin, 2016, 66(2):115-132. doi: 10.3322/caac.21338
[3]	D'Angelo SP, Pietanza MC, Johnson ML, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas[J]. J Clin Oncol, 2011, 29(15): 2066-2070. doi: 10.1200/JCO.2010.32.6181
[4]	Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence[J]. J Clin Oncol, 2005, 23(11):2513-2520. doi: 10.1200/JCO.2005.00.992
[5]	Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase Ⅲ trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) [J]. Ann Oncol, 2013, 24(1):54-59. doi: 10.1093/annonc/mds214
[6]	Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) [J]. J Thorac Oncol, 2014, 9(2):154-162. doi: 10.1097/JTO.0000000000000033
[7]	Wu T, Hsiue EH, Lee J, et al. New data on clinical decisions in NSCLC patients with uncommon EGFR mutations[J]. Exp Rev Respirat Med, 2016, 11(1):51-55. doi: 10.1080/17476348.2017.1267569?src=recsys
[8]	Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUXLung 2, LUX-Lung 3, and LUX-Lung 6[J]. Lancet Oncol, 2015, 16(7): 830-838. doi: 10.1016/S1470-2045(15)00026-1
[9]	Improta G, Pettinato A, Gieri S, et al. Epidermal growth factor receptor exon 20 p.S768Ⅰ mutation in non-small cell lung carcinoma: a case report combined with a review of the literature and investigation of clinical significance[J]. Oncol Letters, 2015, 11(1):393-398. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727163/
[10]	Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics[J]. Mol Cancer Ther, 2013, 12 (2):220-229. doi: 10.1158/1535-7163.MCT-12-0620
[11]	Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy[J]. Cancer Science, 2016, 107(9):1179-1186. doi: 10.1111/cas.12996
[12]	李婧, 黄建安.EGFR基因20外显子点突变在非小细胞肺癌中的研究进展[J].中华医学杂志, 2016, 96(48):3925-3928. doi: 10.3760/cma.j.issn.0376-2491.2016.48.019 Li J, Huang JA. Advances of point mutation of exon 20 of EGFR gene in non-small cell lung cancer[J]. Natl Med J China, 2016, 96(48):3925-3928. doi: 10.3760/cma.j.issn.0376-2491.2016.48.019
[13]	Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(3):239-246. doi: 10.1016/S1470-2045(11)70393-X
[14]	Pallan L, Taniere P, Koh P. Rare EGFR exon 20 S768Ⅰ mutation predicts resistance to targeted therapy: a report of two cases[J]. J Thorac Oncol, 2014, 9(10):e75. http://www.ncbi.nlm.nih.gov/pubmed/25521406
[15]	Weber B, Hager H, Sorensen BS, et al. EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in danish patients with non-small cell lung cancer[J]. Lung Cancer, 2014, 83(2): 224-230. doi: 10.1016/j.lungcan.2013.11.023
[16]	Lund-Iversen M, Kleinberg L, Fjellbirkeland L, et al. Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations[J]. J Thorac Oncol, 2012, 7(9):1471-1473. doi: 10.1097/JTO.0b013e3182614a9d
[17]	Leventakos K, Kipp BR, Rumilla KM, et al. S768Ⅰ Mutation in EGFR in patients with Lung Cancer[J]. J Thor Oncol, 2016, 11(10):1798-1801. doi: 10.1016/j.jtho.2016.05.007
[18]	Longo L, Mengoli MC, Bertolini F, et al. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768Ⅰ mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma[J]. Lung Cancer, 2017, (103):24-26. http://www.sciencedirect.com/science/article/pii/S0169500216305281
[19]	Masago K, Fujita S, Irisa K, et al. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC>ATC in Exon 20 (S768Ⅰ)[J]. Japanese J Clin Oncol, 2010, 40(11):1105-1109. doi: 10.1093/jjco/hyq087
[20]	Heigener DF, Schumann C, Sebastian M, et al. Afatinib in non-small cell lung cancer harboring uncommon EGFR mutations pretreated with reversible EGFR inhibitors[J]. Oncologist, 2015, 20(10):1167-1174. doi: 10.1634/theoncologist.2015-0073
[21]	Cheng G, Song Z, Chen D. Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations[J]. Oncol Targets Ther, 2016, (9):4181-4186. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944908/figure/f2-ott-9-4181/
[22]	Zhu X, Bai Q, Lu Y, et al. Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768Ⅰ: a retrospective analysis and literature review [J]. Target Oncol, 2017, 12(1):81-88. doi: 10.1007/s11523-016-0455-4
[23]	Zhang Y, Wang Z, Hao X, et al. Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations[J]. Chin J Cancer Res, 2017, 29(1):18-24. doi: 10.21147/j.issn.1000-9604.2017.01.03
[24]	Klughammer B, Brugger W, Cappuzzo F, et al. Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations[J]. J Thora Oncol, 2016, 11(4):545-555. doi: 10.1016/j.jtho.2015.12.107
[25]	Chiu C, Yang C, Shih J, et al. Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768Ⅰ mutations[J]. J Thora Oncol, 2015, 10(5):793-799. doi: 10.1097/JTO.0000000000000504
[26]	Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict treatment outcome of stage ⅢB/Ⅳ patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy [J]. J Clin Oncol, 2008, 26(16):2745-2753. doi: 10.1200/JCO.2007.15.6695
[27]	Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response[J]. Clin Cancer Res, 2008, 14(15):4877-4882. doi: 10.1158/1078-0432.CCR-07-5123
[28]	Beau-Faller M, Prim N, Ruppert AM, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network [J]. Ann Oncol, 2014, 25(1):126-131. doi: 10.1093/annonc/mdt418
[29]	Weber B, Hager H, Sorensen BS, et al. EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer[J]. Lung Cancer, 2014, 83(2):224-230. doi: 10.1016/j.lungcan.2013.11.023
[30]	Kobayashi Y, Togashi Y, Yatabe Y, et al. EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first-or third-generation TKIs [J]. Clin Cancer Res, 2015, 21(23):5305-5313. doi: 10.1158/1078-0432.CCR-15-1046
[31]	Svaton M, Pesek M, Chudacek Z, et al. Current two EGFR mutations in lung adenocarcinoma-case report[J]. Klin Oncol, 2015, 28(2):134-137. https://www.ncbi.nlm.nih.gov/pubmed/25882025
[32]	Kobayashi S, Canepa HM, Bailey AS, et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors[J]. J Thorac Oncol, 2013, 8(1):45-51. doi: 10.1097/JTO.0b013e318274a83e
[33]	Beau-Faller M, Prim N, Ruppert AM, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network[J]. Ann Oncol, 2014, 25(1):126-131. doi: 10.1093/annonc/mdt418
[34]	Asahina H, Yamazaki K, Kinoshita I, et al. Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768Ⅰ and V769L[J]. Lung Cancer, 2006, 54(3):419-422. doi: 10.1016/j.lungcan.2006.09.005
[35]	Cheng C, Wang R, Li Y, et al. EGFR exon 18 mutations in east asian patients with lung adenocarcinomas: a comprehensive investigation of prevalence, clinicopathologic characteristics and prognosis [J]. Sci Rep, 2015, 5(1):13959. doi: 10.1038/srep13959
[36]	Cho J, Bass AJ, Lawrence MS, et al. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab[J]. Mol Cancer, 2014, (13):141. http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24894453/
[37]	Gatalica Z, Vranic S, Ghazalpour A, et al. Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast[J]. Oncotarget, 2016, 7(2):1707-1716. doi: 10.18632/oncotarget.v7i2
[38]	杨雪, 陈含笑, 张弘, 等.NSCLC携带EGFR少见突变分析及EGFRTKIs疗效初步观察[J].中国肺癌杂志, 2015, 18(8):493-499. doi: 10.3779/j.issn.1009-3419.2015.08.04 Yang X, Chen HX, Zhang H, et al. Effectiveness of tyrosine kinase inhibitors on uncommon epidermal growth factor receptor mutations in non-small cell lung cancer][J]. Chin J Lung Cancer, 2015, 18(8):493-499. doi: 10.3779/j.issn.1009-3419.2015.08.04
[39]	Kobayashi H, Wakuda K, Takahashi T. Effectiveness of afatinib in lung cancer with paralytic ileus due to peritoneal carcinomatosis [J]. Respir Case Rep, 2016, 4(6):e197. https://www.ncbi.nlm.nih.gov/pubmed/28031832/
[40]	Russo A, Franchina T, Ricciardi GRR, et al. Rapid acquisition of T790M mutation after treatment with afatinib in an NSCLC patient harboring EGFR exon 20 S768Ⅰ mutation[J]. J Thora Oncol, 2017, 12(1):e6-8. doi: 10.1016/j.jtho.2016.09.132
[41]	Tanizaki J, Banno E, Togashi Y, et al. Case report: durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation[J]. Lung Cancer, 2016, (101): 11-15. https://www.sciencedirect.com/science/article/pii/S0169500216304640
[42]	Banno E, Togashi Y, Nakamura Y, et al. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768Ⅰ: what is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor[J]? Cancer Sci, 2016, 107(8):1134-1140. doi: 10.1111/cas.2016.107.issue-8
[43]	Chen YR, Fu YN, Lin CH, et al. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants[J]. Oncogene, 2006, 25(8):1205-1215. doi: 10.1038/sj.onc.1209159
[44]	Kancha RK, von Bubnoff N, Peschel C, et al. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy[J]. Clin Cancer Res, 2009, 15 (2):460-467. doi: 10.1158/1078-0432.CCR-08-1757
[45]	Kuiper JL, Hashemi SMS, Thunnissen E, et al. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment[J]. Bri J Cancer, 2016, 115(12): 1504-1512. doi: 10.1038/bjc.2016.372